AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03572387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron
Description: 7.5 mg x 1
Study NCT03572387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron
Description: 7.5 mg x 1
Study NCT04421846 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Description: Collection of biological samples and clinical/paraclinical data
Study NCT02850510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Incredible Years parent training
Description: The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
Study NCT01231009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
Study NCT01231009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
Study NCT01231009 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular exercises
Description: Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
Study NCT01231009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vestibular exercises
Description: Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
Study NCT01992601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)
Description: For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period.
Study NCT03599570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP-HPV performance feedback intervention
Description: This intervention will be the addition of performance feedback (in the presence of communication skills).
Study NCT02678117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin & Placebo
Study NCT02678117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate & Placebo
Study NCT03401008 — intervention group
Intervention type: OTHER
Intervention: Oral manifestations
Description: To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
Study NCT02678117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin & Magnesium sulphate
Study NCT02678117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00374634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH drug dose
Description: Individual rFSH dose (50, 75 or 100 IU rFSH/day)
Study NCT00374634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard rFSH dose
Description: Standard rFSH dose was 75 IU/day
Study NCT00927199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Oleic Canola Oil
Description: Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
Study NCT00927199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Oleic Canola/Flaxseed Oil Blend
Description: Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
Study NCT01010659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimal Tube
Description: Lacrimal Tube
Study NCT03280589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sheetali/Sheekari Pranayama
Description: Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex \[6\]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
Study NCT03280589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sitting Quietly
Description: Participant breaths in their natural way with out instruction
Study NCT03280589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep breathing
Description: Participant is required to pay attention to each breath
Study NCT00927199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Western Dietary Control
Description: Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
Study NCT01119872 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positive End-expiratory Pressure (PEEP)
Description: All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment.
Study NCT01823939 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: iOWH032
Description: Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032.
Study NCT02351934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT02351934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
Study NCT02351934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
Study NCT02351934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
Study NCT02351934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
Study NCT02423148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Study NCT02423148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluoSCOPE
Study NCT02483026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi vitamin
Description: Multi vitamin
Study NCT02483026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D
Study NCT02483026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: vitamin D
Description: Vitamin D
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMR Referral
Description: EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMR Referral
Description: EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTIS Counseling
Description: Counseling from MotherToBaby teratogen information specialist.
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CTIS Counseling
Description: Counseling from MotherToBaby teratogen information specialist.
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Questionnaire
Description: Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Questionnaire
Description: Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraception Provision Appointment
Description: Appointment with contraception provider to discuss contraception options.
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 Month Follow Up Questionnaire
Description: Questionnaire 3 months after CTIS counseling to assess contraception use and plans
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3 Month Follow Up Questionnaire
Description: Questionnaire 3 months after CTIS counseling to assess contraception use and plans
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 Month Follow Up Questionnaire
Description: Questionnaire 6 months after CTIS counseling to assess contraception use and plans
Study NCT02293213 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6 Month Follow Up Questionnaire
Description: Questionnaire 6 months after CTIS counseling to assess contraception use and plans
Study NCT02028078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin human
Description: Induces hypoglycaemia
Study NCT04535310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision1® Daily Disposable Contact Lens
Description: Soft, spherical contact lens used to correct distance vision.
Study NCT02544451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).
Study NCT02544451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Description: LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).
Study NCT02976571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application
Study NCT02976571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application
Study NCT02976571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Sub cutaneous and/or Intraperitoneal Marcaine application
Study NCT00860847 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aged garlic extract and Coenzyme Q10
Description: AGE (1200 mg) and CoQ10 (120 mg)
Study NCT00532493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually.
Study NCT00532493 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill
Study NCT04445727 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Will apply 1000mg of vitamin C, TENS and manual therapy. One session will be held per week for 6 weeks.
Study NCT02397746 — intervention group
Intervention type: DEVICE
Intervention: total hip arthroplasty implant
Study NCT03556033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 8 weeks treatment with dapagliflozin on top of insulin treatment
Study NCT03556033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 8 weeks treatment with placebo capsules on top of insulin treatment
Study NCT00512525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ghrelin and saline (as placebo)
Description: Intravenous infusion
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses, Phase 2
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Silicone hydrogel contact lenses, Phase 2
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OPTI-FREE® PUREMOIST® MPDS
Description: Contact lens care system, Phase 2
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE® PUREMOIST® MPDS
Description: Contact lens care system, Phase 2
Study NCT04445727 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: spinal manipulation
Description: Applied spinal manipulations, tens and manual therapy.One session will be held per week for 6 weeks.
Study NCT04445727 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Received a manual therapy intervention and Tens. one session will be held per week for 6 weeks.
Study NCT02157701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyherbal capsule
Study NCT02157701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Study NCT02009098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
Study NCT03755375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: transcutaneous electrostimulation to improve the pain.
Study NCT03755375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postural exercises
Description: breathing exercises in the lay-down position, hip anteversion and retroversion in the sitting position, and anteversion, retroversion, and lateral movement in the stand-up position
Study NCT03755375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: pelvic floor muscle coordination and relaxation exercises using intravaginal probes
Study NCT03755375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: myofascial trigger point release maneuver using digital pressure and muscle fiber stretching in pain areas
Study NCT00444275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole (Nexium®)
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Study NCT00444275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xolaam®
Description: This randomized study was conducted on parallel groups and included two phases:~* One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~* One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed
Study NCT02027636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement and Counseling for Latinos (ECLA-F)
Description: The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
Study NCT02027636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement and Counseling for Latinos (ECLA-T)
Description: The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
Study NCT03222388 — intervention group
Intervention type: OTHER
Intervention: Questionnaire - IIEF 5/15
Description: International Index of Erectile Function
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIOTRUE®
Description: Contact lens care system, Phase 2
Study NCT03186573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape juice
Description: 400ml diary of grape juice
Study NCT03186573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 400ml diary of maltodextrin
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIOTRUE®
Description: Contact lens care system, Phase 2
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balafilcon A contact lenses
Description: Silicone hydrogel contact lenses worn for 30 days, Phase 1
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balafilcon A contact lenses
Description: Silicone hydrogel contact lenses worn for 30 days, Phase 1
Study NCT00566592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral ethanol, overnight
Description: Oral ethanol before bedtime to achieve approximate BAL of 0.08%
Study NCT00566592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV ethanol
Description: IV ethanol before bedtime to achieve approximate BAL of 0.08%
Study NCT00566592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: soda water
Description: Oral Placebo before bedtime to achieve approximate BAL of 0.00%
Study NCT00566592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: soda water
Description: Oral Placebo to achieve approximate daytime BAL of 0.00%
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu® Multiplus®
Description: Contact lens care system used for 30 days, Phase 1
Study NCT01699750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu® Multiplus®
Description: Contact lens care system used for 30 days, Phase 1
Study NCT02313402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOL (Eye On Line)
Description: the intervention consists in training program allowing a gradual acquisition of the eye-writing
Study NCT04547816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Description: Biofeedback therapy is a procedure when the patient is taught to make proper squeezing by adequate increase of intra-abdominal and rectal pressures and relaxation of the muscles of the pelvic floor. This procedure is widely described and is to be performed with the use of devices registered for this purpose Urostim and WPM Solar, MMS, the Netherlands